• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

16
13
9
8
6

COUNTRY

6
2
2
1
1

CATEGORIES

  • 25
  • 9
  • 6
  • 4
  • 4
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

13
14
20
56

PUBLISHED

1
7
23
56

PRODUCT TYPE

44
12

Search "Eisai: Pipeline, Products, Performance and Potential" returned 56 results.

PRODUCT TITLE

Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review

Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The...

March 2015
FROM
Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma - Product Thumbnail Image

Global Pharmaceutical & Biotechnology Outlook 2013: Japan Pharma

Global Pharmaceuticals and biotechnology outlook - Japan Pharma The coming years will see Japan pharma regaining its status as innovator driven with Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi...

January 2013
FROM

Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022

Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022”....

February 2013
FROM

VX-765 (Epilepsy) - Forecast and Market Analysis to 2022

VX-765 (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “VX-765 (Epilepsy) - Forecast and Market Analysis to 2022”. Epilepsy...

February 2013
FROM

Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022

Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Brivaracetam (Epilepsy) - Forecast and Market Analysis to...

February 2013
FROM

Halaven ( Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Halaven ( Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis...

February 2013
FROM

PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022”....

February 2013
FROM

PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to...

February 2013
FROM

PharmaPoint: Epilepsy - US Drug Forecast and Market Analysis to 2022

Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction The...

February 2013
FROM

PharmaPoint: Alzheimer's Disease - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - Japan Drug Forecast and...

July 2013
FROM

Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

What Will the Pharma Industry Look Like in 5 Years? There are an estimated 724 projects in development from the top 50 pharmaceutical companies.  Together, they have the potential to add billions...

August 2012
FROM

Pharmaceutical Products of the Future: 50-Company Pipeline Analysis to 2015

What Will The Pharmaceutical Market Look Like in the Next Five Years? In this report, Kalorama has analyzed the late stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies...

July 2010
FROM

Shionogi & Co., Ltd. (4507) - Financial and Strategic SWOT Analysis Review

Shionogi & Co., Ltd. (4507) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled...

July 2014
FROM

Merck & Co., Inc. (MRK) - Financial and Strategic SWOT Analysis Review

Merck & Co., Inc. (MRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The...

March 2015
FROM
Loading Indicator

Our Clients

Goodyear Tire & Rubber Company GlaxoSmithKline PLC Hilton Worldwide Hewlett-Packard Company Accenture PLC. Qualcomm Incorporated UBS AG